Specifically for spasticity-related MS, it has been observed in clinical trials and real-world studies that by using an oromucosal spray containing a mixture of 9-δ-tetrahydrocannabinol and cannabidiol (THC:CBD), nabiximols, which target CB1 and CB2 receptors to treat spasticity in MS patients, an control is gained over a broader range of symptoms that constitute the main proposal of the SPS (5–13). This evidence concerns the gene CNR1 and myeloid sarcoma.